Q-omics provides the consensus-scored RN7SL648P profile across patient tissues and cancer cell-line models. RN7SL648P expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, RN7SL648P is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, RN7SL648P RNA expression shows 13,518 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, COAD, and UVM as cancer lineages where RN7SL648P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL648P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL648P survival associations across molecular data types. RN7SL648P RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL648P RNA expression–survival associations across cancer types. High RN7SL648P expression shows unfavorable associations in MESO, LUSC, READ, THCA and ESCA, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .010). Together, the overview and detailed table identify UCS as the clearest survival context for RN7SL648P RNA expression.
This table summarizes RN7SL648P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL648P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL648P shows lower tumor expression in LUAD, BRCA and ESCA and higher tumor expression in COAD, KIRP and KIRC. The COAD box plot shows higher RN7SL648P RNA expression in tumor versus normal tissue (log2 FC = +0.521, t-test p = .014).
This table shows molecular features associated with RN7SL648P in patient tissues and cancer cell lines. In patient samples, RN7SL648P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
